Trial Profile
A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Enzalutamide (Primary) ; Nivolumab (Primary) ; Rucaparib (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CheckMate 9KD
- Sponsors Bristol-Myers Squibb
- 28 Mar 2024 Planned End Date changed from 1 Feb 2025 to 15 Sep 2024.
- 01 Mar 2024 Planned End Date changed from 28 Jun 2024 to 1 Feb 2025.
- 21 Dec 2023 This trial has been completed in Germany.